The Vaginal Mesh Helpline is keeping you up to date on all the vaginal mesh lawsuit news. There are new developements in the vaginal mesh trials. Judge Higbee has ordered Ethicon, a subsidiary of Johnson & Johnson, to release post-marketing safety data and FDA correspondence related to its mesh products. The data is likely to include safety information the FDA requested in January 2012 from 30 transvaginal mesh device manufacturers. The FDA asked for 3 years of data on the safety and effectiveness of various mesh products.

New Data of Interest to Vaginal Mesh Victims and Their Vaginal Mesh Lawyers

Vaginal mesh lawyers are expected to review the newly released safety data on Ethicon’s products. The information may reveal key information about how the company brought its products to market, and about how much it knew about serious safety risks and complications.

Vaginal mesh may be used in the treatment of pelvic organ prolapse. This exists when a woman’s pelvic muscles become overly stretched and weakened due to multiple childbirths, surgery, or aging. The muscles may allow the bladder, uterus, or bowel to drop or fall into the vaginal wall because they are not able to adequately support pelvic organs. This may cause symptoms like pressure and urinary incontinence.

Gynecare mesh and similar mesh products were designed to provide support and help pelvic organs back into their original position. This helps to reduce urinary incontinence and other symptoms. Post-marketing reports, however, indicate that women are experiencing more pain and discomfort than prior to the surgery.

On July 13, 2011, the FDA released a safety communication noting that complications from transvaginal mesh repair for pelvic organ prolapse are not rare. The FDA also noted that even multiple corrective surgeries may not fully correct problems like erosion and infection. Other side effects may include organ perforation, bleeding, continued urinary problems, painful sexual intercourse, mesh extrusion, and recurrence of pelvic organ prolapse.

Currently, thousands of women are involved in transvaginal mesh lawsuits around the country. In addition to products made by Ethicon, other manufacturers named as defendants include American Medical Systems, C. R. Bard, Boston Scientific, and Coloplast.

Johnson & Johnson Pulls Four Gynecare Products from Market

With over 600 vaginal mesh lawsuits currently pending in state and federal courts, Johnson & Johnson and Ethicon have stopped selling four vaginal mesh implants. In correspondence filed June 4, 2012, the companies told Judge Joseph R. Goodwin, who is overseeing the current vaginal mesh MDL in the U.S. District Court in West Virginia, that they would cease commercializing the four products and plan to phase them out completely by early 2013.

Products included in the phase-out include:

    Gynecare TVT Secur
    Gynecare Prosima Pelvic Floor Repair System
    Gynecare Prolift Pelvic Floor Repair System
    Gynecare Prolift MTM Pelvic Floor Repair System

Despite this move, the companies will still be expected to release safety data regarding these four products for the New Jersey litigation.

The Gynecare Prolift device was the subject of an earlier controversy, when documents released from a New Jersey lawsuit revealed that Johnson & Johnson continued to sell the mesh even after the FDA directed the company to halt sales because the device lacked the appropriate clearance.

We will continue to keep you updated as new developements occurr.

The Vaginal Mesh Helpline will keep you updated on all the most recent news. Our vaginal mesh network of lawyers is filing mesh lawsuits on behalf of women with a failed Prolene mesh. The mesh was used for urinary incontinence in 100's of women.

Published on Saturday 15 September 2012 21:02

Botox injections may help women with urinary incontinence, The Daily Telegraph has today reported. The newspaper said that injecting the muscle-freezing toxin into the wall of the bladder can have a long-lasting impact on overactive bladder syndrome, a major cause of incontinence.

The newspaper’s story is based on a UK medical trial that investigated whether the paralysing properties of botox were effective at reducing the symptoms such as frequently using the toilet, feeling an urgent need to urinate, and leakage in patients with overactive bladder syndrome.

The trial featured 240 women who had not responded to medical treatments for overactive balder syndrome. The researchers found that women who received the botox injection experienced these symptoms significantly less frequently than women who received a dummy injection of saltwater. However, women given botox were more likely to get urinary tract infections.

The results of the study indicate that botox may be effective in treating a common and upsetting health condition. However, if it does get adopted into use in this way there are several other treatment options (including lifestyle measures, bladder training exercises and medication that would be considered first. Botox may be considered as an option only if these treatments fail, and the benefits would have to be considered in relation to its potential harms.

Where did the story come from?

The study was carried out by researchers from the University of Leicester and was funded by the Moulton Charitable Trust and the women’s health charity Wellbeing of Women.

The study was published in the peer-reviewed medical journal European Urology.

The Telegraph covered this study appropriately, covering the study size and design, as well as the treatment benefits and harms.

What kind of research was this?

While it is hard to gauge the true scale of the problem, research suggests that around 13% of women in the UK may have some form of urinary incontinence. Although many conditions and factors can cause urinary incontinence, one major cause is overactive bladder syndrome. The condition is marked by uncontrolled contraction of the bladder that results in an urgent need to pass urine. While this can lead women to need the toilet frequently, some also experience a form of leakage called urge incontinence.

An overactive bladder can be a cause of urge incontinence, which is when urine leaks at the same time or just after you feel an intense urge to pass urine. Urge incontinence differs from stress incontinence, where the pelvic floor muscles are too weak to prevent urination. This causes urine to leak when your bladder is placed under pressure from actions such as coughing or laughing.

This was a placebo-controlled randomised controlled trial that examined the effectiveness and safety of using botulinum toxin (botox) as a treatment for overactive bladder syndrome. A randomised controlled trial is the best way to measure the effectiveness of a treatment, as the randomisation process helps to ensure that any patient characteristics that may influence the outcome have an equal chance of appearing in either treatment group. This allows researchers to be confident that any observed effect is due to the treatment under study.

What did the research involve?

The researchers enrolled 240 women with bladder muscle overactivity, or overactive bladder syndrome, that had not responded to previous treatment. The women were randomly allocated injections of either Botulinum toxin A (botox) or placebo (saltwater) into the wall of the bladder. Women with another common type of incontinence, stress incontinence, were not included in the study.

The participants kept a diary over three days, recording the number of times they:

    emptied their bladder
    felt an urgent need to empty their bladder
    experienced an unintentional passing of urine (or leakage)

The women also completed a questionnaire that assessed their quality of life, as overactive bladder syndrome often has a significant negative impact on patient quality of life.

The researchers conducted follow-up sessions with the women on average at six weeks, three months and six months after treatment. They assessed differences in the frequency of the above three symptoms between the two treatment groups. They also compared quality of life scores, treatment complications and time until troubling symptoms returned between the two groups.

The researchers used appropriate statistical methods to assess differences in frequency of symptoms between the two groups.

What were the basic results?

There were 122 women allocated to the botox treatment group and 118 women allocated to the placebo group.

The researchers compared the outcomes in the botox and placebo groups at the six-month follow-up. They found that in any 24-hour period women in the botox group:

    emptied their bladders less often: 8.33 times versus 9.67 times, a difference of 1.34 (95% confidence interval [CI] 1.00 to 2.33, p=0.0001)
    experienced fewer leakage episodes: 1.67 versus 6.00, a difference of 4.33 episodes (95% CI 3.33 to 5.67, p<0.0001)
    experienced fewer episodes of urgency to urinate: 3.83 versus 6.33, a difference of 2.50 episodes (95% CI 1.33 to 3.33, p<0.0001)

Almost a one-third of women in the botox group (31.3%) developed bladder control (or continence) following their treatment, compared to 12.0% in the placebo group (Odds Ratio [OR] 3.12, 95% CI 1.49 to 6.52, p=0.002).

However, urinary tract infection was reported at least once during six months by a one-third of women in the botox treatment group, compared to 10% in the placebo group (OR 3.68, 95% CI 1.72 to 8.25, p=0.0003).

Those given botox also reported greater difficulty emptying their bladders, which required self-catheterisation to remove their urine: 16% of the botox group compared to 4% of the placebo group (OR 4.87, 95% CI 1.52 to 20.33, p=0.003).

How did the researchers interpret the results?

The researchers concluded that injections of botulinum toxin A into the bladder wall is an effective and safe treatment for overactive bladder syndrome in women who have not responded to previous treatment.

Conclusion

Urinary incontinence can be a distressing and problematic condition, and although we cannot be sure of the number of people affected, research suggests it is surprisingly common.

While there is a range of potential treatments and ways to manage urinary incontinence (including medication, bladder training, lifestyle changes and surgery) not all people respond to them, and they can have problems. This randomised controlled trial provided good evidence that botox injections may be a useful treatment option for women with incontinence due to overactive bladder syndrome that has proven difficult to treat with other methods.

The researchers say that the relief of symptoms reported by the participants was considerably better than those who used oral anticholinergic drugs. These drugs act on the nerve supply to the bladder and are the standard medical treatment used for this condition. They add that other randomised controlled trials have reported similar effects.

The researchers say that since they designed their trial, other studies have published results that support using a lower recommended dose of botox for this type of treatment. Therefore, it is unclear if the same results would be found at this reduced dose. They also say that their study recruited participants with severe cases of overactive bladder syndrome, and that it is unclear if the treatment would be as effective in less severe cases.

It is important to note that the study participants did not have stress incontinence, which is a common cause of urinary incontinence. Therefore, the results of this study cannot be generalised to all women with symptoms of overactive bladder or incontinence, but can only be applied to those with diagnosed overactive bladder syndrome (or detrusor overactivity).

Botox is not routinely used by the NHS in this way, but if it were then it would probably be considered as an option only among women who have required specialist referral for their condition. This would be given after they had tried other treatment options first, which may include lifestyle measures and bladder training exercises in addition to oral medications. If these treatments fail, the benefits of botox would have to be considered in relation to its potential harms.

The dates have been set to begin two manufacturers vaginal mesh trials. Vaginal mesh lawyers will begin the steps to bring justice to 1000's of women whose lives and bodies have turned to turmoil by a Prolene plastic mesh. The mesh was originally tauted as the cure all for urinary  incontinence, bladder, bowel and uterine prolapse. But, there were problems and the adverse incident reports and warnings began to surfice. In 2008 a warning was issued by the FDA.  As these mesh lawsuit trials begin we will hopefully begin to bring justice to the tens of thousands of women injured by the mesh.This is just the beginning and there is still time to file your mesh lawsuit.

Vaginal Mesh Lawsuit Trials Are Ready to Begin

Ethicon Gynecare Trials to Begin Next Year

The first Ethicon Gynecare pelvic mesh lawsuits are scheduled to go before a jury near the end of next year in New Jersey state court. Thes will be presented by lead vaginal mesh lawyers.

Judge Carol E. Higbee, who is overseeing the consolidated Ethicon vaginal mesh lawsuits in New Jersey Superior Court, has scheduled the first Ethicon Gynecare test cases, known as bellwether trials, to begin in November 2012.

Preliminary discovery for cases being prepared for early trial dates is to be completed by March 30, and expert witnesses are to be deposed by October 5, according to a scheduling order Judge Higbee issued on October 28.

More than 350 lawsuits over Ethicon Gynecare transvaginal mesh have been centralized under Higbee for pretrial proceedings.

The cases involves women who received Gynecare Prolift mesh, Gynecare Gynemesh, Gynecare Prolene mesh, Gynecare TVT sling or another pelvic mesh product manufactured by Ethicon.

Bard Trials To Begin Next Year

C.R. Bard Inc. will face its first federal-court trial next year over claims that the company’s vaginal-mesh implants injured women.

U.S. District Judge Joseph R. Goodwin in Charleston, West Virginia, set a Feb. 5 trial date for the first of about 600 federal cases contending that Bard’s Avaulta device caused organ damage. Goodwin is overseeing a consolidation of cases filed in federal courts across the U.S. against Bard, Johnson & Johnson and other makers of vaginal-mesh inserts.

The order of trials for the first federal cases over Avaulta “will be determined after completion” of pretrial information exchanges between Bard and the plaintiffs, Goodwin said in his order yesterday.

We will continue to report as the news comes out.

The Vaginal Mesh Helpline lawsuits lawyers  and the Mesh Helpline are keeping women updated on all new vaginal Mesh lawsuit news. Coloplast has been added to the Multi district mesh lawsuits. Their brands are listed below.

 Coloplast Products Have Been  Named in The Vaginal Mesh Lawsuits
According to their website, Coloplast develops products and services “to make life easier for people with deeply personal and private medical conditions.” The company has a special focus on surgical urology, developing surgical devices for both men and women. For women, Coloplast markets products to treat pelvic organ prolapse and to control urinary incontinence.
The August 6 order by the JPML centralized 13 Coloplast pelvic mesh lawsuits into West Virginia. All plaintiffs allege that the company’s products caused serious injuries. The products at issue in these lawsuits, Novasilk, Exair, Suspend, and Axis, are used to treat pelvic organ prolapse by supporting weakened pelvic muscles.
Consolidation into one court helps conserve resources, increase efficiency, and reduce the risk of duplicative discovery or conflicting rulings from other courts. Each lawsuit retains its individual nature, however, and will be returned to its original court for trial after pre-trial proceedings are complete.

Wome are advised to file litigation immediately to avoid being closed out due to a staute of limitation issue in your state. All the noted mesh ccomplications are being seen in these mesh devices.

Coloplast Lawsuits

• Novasilk
• Exair
• Suspend
• Axis

The vaginal mesh lawsuits are heating up. Thousands of new cases are being filed in a total of 6 MDL's (Multi-District Litigations ).

Wome are being to figure our it is the mesh despite what their doctors are telling them. They are shouting  for justice for a Prolene mesh product that has wrecked havoc on their bodies and marriages. The majority of women implanted with either a vaginal mesh or bladder sling cannot have sexual intercourse.

Women are in pain and the complications and horrific stories of a failed mesh we hear on a  daily  basis are increasing. Women are seeing the vaginal mesh lawyer lawsuit ads on T.V and it is all starting to make sense and come together. They call for help in locating a doctor and lawyer that they can trust.

In response to this the Vaginal Mesh Helpline now has a network of pre-screened lawyers and is working to compile a list of trusted doctors.

Contact us today for a vaginal mesh lawsuit lawyer and doctor.

Nationwide Vaginal Mesh Lawyer Network Launched

In a response to confusion and the daily questions from women with a malfunctioning vaginal mesh the Vaginal Mesh Helpline now has a group of experienced. caring. pre-screened vaginal mesh lawyers. The Vaginal Mesh Helpline has launched the Vaginal Mesh Lawyer Network. We are reaching out to all women with a failed mesh to encourage you to file your vaginal mesh lawsuit today. Statute of limitations in many states are running close and it is too late for some vaginal mesh lawsuits already. Let us help you locate a vaginal mesh lawyer today.

Vaginal Mesh Complications Are Real

• Mesh erosion into the vaginal canal
• Bleeding
• Severe relentless pain
• Pain on one side of the body
• Lower back pain
• Bowel, Bladder discomfort
• Increased incontinence or difficulty voiding
• Bowel incontinence
• Stomach pain
• Neurological damage
• Pain standing for long periods
• Inabilty to work
• Inability to have sexual intercourse
• Depression

You have suffered form the mesh and deserve justice. However, with so many lawyers advertising for the vaginal mesh it is hard to choose. Our pre screened lawyers meet very specific criteria. Call for a vaginal mesh lawyer today.

Vaginal Mesh Helpline reports that  a women has finally had enough and protests the vaginal mesh. The Vaginal Mesh Helpline and vaginal mesh lawyers applaud. Perhaps this will become a trend and we will begin to see protests thru-out the country. and is being offered to our readers.
The Vaginal Mesh Helpline is gearing up for what they feel is a second round outreach to some of the largest cities in the United States. "We expect a new wave of T.V ads by lawyers after the election and we are ready."" Women see lawyer ads on T.V and they have alot of questions".Says the helpline medical social worker."They want to speak to someone they feel safe and comfortable with and they call us".

The vaginal mesh lawsuit proceedings have begun" We want all women covered and we want them to get medical and legal help", the helpline representatives tell us. "We have the staff and capacity to help women by offering support and guidance"."They just feel more comfortable with a  social worker then a law firm"

The outreach is a massive undertaking for the Vaginal Mesh Helpline. Their mission is clear and they are ready. They expect to be adding 5-10 new cities a week until they have the major cities in the U.S covered.  The helpline is seeking all women who have not filed their vaginal mesh lawsuit "to stand up and seek justice"

The first round Vaginal Mesh Outreach projected reach the following cities to be:

New York, N.Y.,
Los Angeles, Calif., http://www.vaginalmeshhelpline.com
Chicago, Ill.,
Houston, Tex.,
Philadelphia, Pa,.
Phoenix, Ariz,.
San Antonio, Tex.,
San Diego, Calif.,
Dallas, Tex.,
San Jose, Calif.,

Second vaginal mesh Outreach Campaign

Jacksonville, Fla., http://www.vaginalmeshhelpline.com
Indianapolis, Ind.,
San Francisco, Calif.,
Austin, Tex., http://www.vaginalmeshhelpline.com
Columbus, Ohio,
Fort Worth, Tex.,
Charlotte, N.C.,
Detroit, Mich.,
El Paso, Tex.,
Memphis, Tenn.,

Third round of Vaginal Mesh Outreach

Baltimore, Md.,
Boston, Mass.,
Seattle, Wash.,
Washington, DC,
Nashville,
Denver, Colo.,
Louisville,
Milwaukee, Wis.,
Portland, Ore.,
Las Vegas, Nev.,

Additional Vaginal Mesh Lawsuits Outreach

Oklahoma City, Okla,
Albuquerque, N.M.,
Tucson, Ariz.,
Fresno, Calif.,
Sacramento, Calif.,
Long Beach, Calif.,
Kansas City, Mo.,
Mesa, Ariz.,
Virginia Beach, Va.,
Atlanta, Ga.,
Colorado Springs, Colo.,
Omaha, Nebr.,
Raleigh, N.C.,
Miami, Fla.,
Cleveland, Ohio,
Tulsa, Okla.,
Oakland, Calif,.
Minneapolis, Minn.,
Wichita, Kans.,
Arlington,,

The Vaginal Mesh Helpline is always keeping women updated on new related vaginal mesh news, medical information and vaginal mesh lawsuits. We just found this article and are sharing it with our followers.

Botox Approved, Again, This Time for Urinary Incontinence
By Meredith Melnick | @meredithcm | August 26, 2011 | 54For those of you who have been keeping track, Botox, the symbol of vanity and Bravo’s Real Housewives, actually has a variety of medical uses: it’s government-approved to treat chronic migraines, muscle problems, underarm sweating and a number of other conditions. Now add to that, urinary incontinence.

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Botox, or botulinum toxin, to treat incontinence in patients with neurological conditions like spinal cord injury and multiple sclerosis. It’s the seventh condition that Botox has been approved to treat since the drug first arrived on the market as a wrinkle reducer in 2002.

How does it treat urinary incontinence? In some patients with neurological conditions, overactivity in the bladder leads to an inability to store urine. By injecting Botox directly into the bladder to relax it, patients are offered for more muscle control and less incontinence.

In two clinical trials involving 691 patients with incontinence due to spinal cord injury or multiple sclerosis, those who got Botox had a significant reduction in weekly incontinence episodes, compared to a placebo group, the FDA said. The most common adverse effects were urinary tract infection and urinary retention.

Given that incontinence is so difficult to manage — typically involving drugs to relax the bladder and the use of a catheter to empty it — Botox may give some patients another option. One injection may help control incontinence for up to 10 months, the FDA said.

The approval also opens the door to yet more uses for Botox, made by Allergan, the New York Times reported:

    The drug has been studied for more than 100 medical conditions in all, according to Caroline Van Hove, company spokeswoman. “Anything from writer’s cramp to anal fissure to Parkinson’s disease. That’s why we say it’s a pipeline in a vial,” she said Wednesday.

Botox sales reached about $1.5 billion worldwide in 2010, roughly split between cosmetic and therapeutic purposes.

Perhaps this is something that can help after mesh removal. Our vaginal mesh lawyers are currently filing vaginal mesh lawsuits.

As lawyers thru-out the country jump on the vaginal mesh lawsuits women are searching for urogynecologists or any doctor that can help them. It starts to become obvious that we are not dealing with a product liability that will be easy to assess. The FDA has not pulled them off the market and Docgors are still putting them in despite the warnings. Doctors appear to be stuck between the complications versus the cure for women with severe prolapse. Yet, the horror stories we hear on a daily basis put us in awe. Why are doctors still putting them in ?

We must wonder with all this is mind when is the actual statute of limitations and will we have to send women away who are suffering severe side effects from these mesh devices

The statute of limitations for mesh litigants becomes  very tricky within the law. According to  Transvaginal mesh a lawyers, there are a lot of issues that  arise or things that  just need to be discussed and reviewed regarding a statute of limitations. it is distressing  to think if a woman  is in a state with a one year statute of limitations and had their surgery five years ago that  she cannot do anything about it. The complications are so severe and life altering this would be a travesty. However, that's simply not always the situatuon.  That is where a transvaginal mesh lawyer can help you.
actually, i there are a  number of key dates that can affect when your statute of limitations actually started to run. what is so interesting  is that there's not always one correct answer.  There is  the date in which you had your initial surgery. Then there is the date in which you had the mesh removed.  Then we must examine the date in which the U.S. Food & Drug Administration (FDA) came out with a warning. There is the  date that the early clinical trial ended in 2010. The date in which your doctor convinced you to have the surgery.There is also  the date when you first started noticing your symptoms. There is also the date you may have had it removed.
Now the manufacturers  will  go for the earliest date to help their case. However, what  injured women do not realize is that any of those dates are arguable as a number of factors go into determining when someone's statute of limitations started to run.   Do not to assume that your opportunity has passed and you are out of luck.  If you are suffering from the mesh  take a chance and call a Vaginal mesh lawyer lawyer at the Vaginal Mesh Helpline. You may think it is too late but , you may be  astonished  to find out that one of our vaginal mesh lawyers may tell you it  is not too late at all.

We spesak to women on a daily basis who are suffering and frightened. Our message is do not give up. 300,000 women have been implanted with vaginal mesh implants and as a group you can make a difference for each and everyone of you. You must send ther manufacturers a message.

Vaginal mesh helpline supports the victims of the vaginal mesh and reports Johnson and Johnson profits are down.

Charges drag down Johnson & Johnson Q4 profit and the Vaginal mesh helpline takes notice. Ladies do not give up. As a grouo you can be heard.

  NEW BRUNSWICK, New Jersey — Johnson & Johnson said Tuesday that fourth-quarter profit was barely a tenth of what it made a year ago as several charges for recalls, litigation and an acquisition dragged down income. But the health care giant's revenue jumped last year, ending an unprecedented two-year decline.

After those two years were overshadowed by a series of product recalls and other problems, the maker of Tylenol, prescription drugs and medical devices managed to beat Wall Street's forecast for adjusted profit and came in just below its revenue forecast.

The company said net income was $218 million, or 8 cents per share, down from $1.94 billion, or 70 cents a share, a year earlier.

Excluding charges, net income was $3.13 billion, or $1.13 per share.

Revenue totaled $16.26 billion, up from $15.64 billion in 2010's fourth quarter.

Analysts polled by FactSet, on average, expected earnings per share of $1.09 and revenue of $16.28 billion.

"We delivered solid results for 2011, built on the strong growth of our recently launched pharmaceutical products, and continued the steady momentum of new product approvals across all our businesses," CEO Bill Weldon said in a statement.

Revenue fell 3.4 percent in the U.S., to $6.99 billion, but jumped 10.2 percent in foreign countries, to $9.27 billion. The U.S. decline was mostly due to an 8 pecent drop in sales of prescription drugs.

J&J said it expects 2012 earnings of $5.05 to $5.15 per share, excluding special items. Analysts had expected $5.20 per share.

Attention Victims of the Vaginal mesh.  You must contact the helpline for a gynecare mesh lawyer now and list for the vaginal mesh lawsuit. Our voices must be heard. Fight back now. Protect other women.